Zevra Therapeutics

Yahoo Finance • 2 months ago

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement und... Full story

Yahoo Finance • 2 months ago

Zevra Turns Profitable In 2025 On Strong Uptake Of MIPLYFFA For Niemann-Pick Disease Type C

(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) has reported its fourth quarter and full-year 2025 financial results, marking a sharp turnaround from losses in 2024 as sales of its rare disease therapy MIPLYFFA accelerated. MIPLYFFA (Arimoclo... Full story

Yahoo Finance • 3 months ago

Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the pr... Full story

Yahoo Finance • 3 months ago

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that i... Full story

Yahoo Finance • 5 months ago

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that t... Full story

Yahoo Finance • 5 months ago

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the ap... Full story

Yahoo Finance • 6 months ago

Zevra Therapeutics, Inc. Announces CFO Transition

CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that it... Full story

Yahoo Finance • 6 months ago

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

2025 EPS of $(0.01) Q32025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEW... Full story

Yahoo Finance • 6 months ago

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that m... Full story

Yahoo Finance • 6 months ago

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it wil... Full story

Yahoo Finance • 7 months ago

Zevra Therapeutics rises amid takeover speculation

[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images Z... Full story

Yahoo Finance • 8 months ago

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA off... Full story

Yahoo Finance • 8 months ago

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLY... Full story

Yahoo Finance • 8 months ago

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four p... Full story

Yahoo Finance • 8 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

CELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that m... Full story

Yahoo Finance • 9 months ago

Zevra Therapeutics gains amid takeover speculation

[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images Z... Full story

Yahoo Finance • 9 months ago

Zevra Therapeutics stock price target lowered to $18 at Citizens JMP

Investing.com - Citizens JMP lowered its price target on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) to $18.00 from $19.00 on Wednesday while maintaining a Market Outperform rating. According to InvestingPro data, the stock has delivered an imp... Full story

Yahoo Finance • 9 months ago

Zevra Revenue Jumps 486 Percent in Q2

Key Points GAAP revenue rose to $25.9 million in Q2 2025, exceeding estimates by 14.8%, on strong MIPLYFFA sales and French EAP expansion. GAAP net income reached $74.7 million in Q2 2025, reversing a loss from the prior year, but was fue... Full story

Yahoo Finance • 9 months ago

Zevra signals continued MIPLYFFA momentum with 26% revenue growth and $150M PRV sale strengthening balance sheet

Earnings Call Insights: Zevra Therapeutics (ZVRA) Q2 2025 MANAGEMENT VIEW * Neil F. McFarlane, President and CEO, highlighted that "Q2 net revenue reached $25.9 million, reflecting robust demand and effective operational execution." He... Full story

Yahoo Finance • 9 months ago

Earnings call transcript: Zevra Therapeutics Q2 2025 misses EPS, revenue shines

Zevra Therapeutics reported its Q2 2025 earnings, revealing a mixed financial performance. The company posted an earnings per share (EPS) of -$0.06, significantly missing the forecasted $2.19. However, revenue came in at $25.9 million, sur... Full story